MRD
clonoSEQ Assay Authorized for Detection of MRD in Patients With MM and B-Cell ALL
The FDA has authorized use of the clonoSEQ Assay (Adaptive Biotechnologies) to monitor and detect minimal residual ...
OCTOBER 22, 2018
FDA Approves Blincyto for ALL Pts with Minimal Residual Disease
Blincyto is the first and only FDA-approved therapy for patients who have ALL that is in remission but who still ...
MARCH 29, 2018
Load more